このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

頭頸部がんにおけるIL-12を発現するウイルスレプリコン(saRNA)粒子の腫瘍内送達

2026年9月15日 更新者:VLP Therapeutics

頭頸部がんにおける VLPONC-01 の腫瘍内注射の研究

The goal of this clinical trial is to assess the safety and tolerability of a virus replicon particle (VRP) encapsulated saRNA encoding IL-12 when injected into in head and neck cancer patients. The main questions being addressed are:

The safety and tolerability of intratumoral (IT) injections of VRP-encapsulated saRNA encoding IL-12 (VLPONC-01)

The tumor response to IT injections of VLPONC-01

The tumor response due to the combination of IT injections of VLPONC-01 and system IV administration of neoadjuvant pembrolizumab (anti-PD-1) treatment

Researchers will compare neoadjuvant pembrolizumab alone to the combination therapy to see if the combination enhances tumor responses.

調査の概要

詳細な説明

The study is an Open label, Phase I study to determine the safety of IT injected VLPONC-01 as a therapeutic agent in subjects with non-resectable and resectable Head and Neck Cancer Squamous Cell Carcinomas (HCSCC), and secondarily to assess pathologic response and radiological response (assessed by RECIST 1.1 criteria) in the primary tumor and regional lymph nodes. Researchers also will explore tumor microenvironment changes in cytokine levels and cellular responses.

There will be three distinct cohorts enrolling sequentially:

Cohort A: Researchers will enroll unresectable or recurrent/metastatic head and neck cancer with at least 1 injectable tumor not scheduled for tumor resection surgery who will receive four doses of VLPONC-01.

Cohort C: Researchers will enroll HCSCC patients scheduled for tumor resection surgery who will receive four doses of VLPONC-1 and two doses of neoadjuvant pembrolizumab or only two doses of neoadjuvant pembrolizumab prior to tumor resection surgery.

研究の種類

介入

入学 (推定)

41

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Clinical Research Coordinator
  • 電話番号:650-725-9333
  • メール:tpark22@stanford.edu

研究場所

    • California
      • Stanford、California、アメリカ、34305
        • 募集
        • Stanford University
        • コンタクト:
        • 主任研究者:
          • Fred M Baik, MD

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Cohort A - Unresectable or recurrent/metastatic head and neck cancer with at least 1 injectable tumor not scheduled for tumor resection surgery. With one the following prior treatments:

    Subjects must have received a platinum containing chemotherapy regimen, 5-Fluorouracil chemotherapy, taxane based chemotherapy, cetuximab or gemcitabine for treatment of primary tumor in locally advanced, or metastatic settings.

    Subjects must have received an anti-PD-1/ PD-L1 as monotherapy or in combination with chemotherapy.

    Subjects must have progressed following therapy with at least one PD-1 or PD-L1 checkpoint inhibitor (regardless of PD-L1 expression status).

    Prior progression on a PD-1 or PD-L1 checkpoint inhibitor should be unequivocal; progression that occurs within the first 8 weeks of treatment on these agents should be confirmed with a second CT at least 4 weeks apart (to exclude pseudo-progression).

    Patients with activating EGFR mutation or ALK rearrangement which is expected to be responsive to available tyrosine kinase inhibitor therapy, therefore these subjects must have been previously treated with an applicable tyrosine kinase inhibitor.

    OR Cohort C - Patients with at least 1 measurable resectable lesion clinical stage I-IVb (cT1-4, N0-3) (AJCC, 8th Edition) (Amin, 2017), Histologically or cytologically confirmed HNSCC. Scheduled to undergo tumor surgical resection of the primary tumor.

  2. Eastern Cooperative Oncology Group (ECOG) performance status 0-1, and adequate bone marrow and organ function.

  3. Primary tumors should be amenable to intratumoral (IT) injection >1 cm diameter. This will be determined by the Protocol Director, or the surgeon involved.

  4. Subjects with either a local recurrence or a new primary tumor will be allowed.

  5. Age ≥ 18 years.

  6. Have acceptable organ and marrow function defined as follows:

    Absolute neutrophil count ≥ 1,500/mcL Platelets ≥ 100,000/mcL Hemoglobin ≥ 8.0 g/dL (Note: use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dL is acceptable) Total bilirubin ≤2x institutional upper limit of normal (ULN) AST(SGOT) or ALT(SGPT) ≤ 3.0x institutional ULN

  7. Ability to understand and the willingness to provide written informed consent.

  8. Life expectancy > 12 weeks (about 3 months).

  9. Patients must be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.

Exclusion Criteria:

  1. Tumors which are not feasible for injections include high risk lesions that are near vital organs or important neurovascular structures, as determined by the Protocol Director or involved surgeon.
  2. Women of childbearing potential must have a negative serum β-hCG pregnancy test within 7 days prior to the administration of the first study treatment and/or urine pregnancy 48 hours prior to the administration of the first study treatment. Both sexually active women of childbearing potential and males (and their female partners) patients must agree to use two methods of effective contraception, one of them being a barrier method, or to abstain from sexual activity during the study and for at least 6 months after last dose of study drugs.
  3. Patients expected to receive other anti-cancer medication such as, chemotherapy, immunotherapy, biologic therapy, targeted therapy, monoclonal antibodies, hormonal therapy (other than leuprolide or other GnRH agonists) prior to surgery and where all acute toxicity of prior treatments have not resolved.
  4. Participation in another clinical study with an investigational product during the last 30 days.
  5. Uncontrolled intercurrent illness including, that do not respond to active medical intervention.
  6. Current or prior use of immunosuppressive medication within 28 days before the first dose of injection, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone or an equivalent corticosteroid.
  7. If applicable: Women who are breastfeeding.
  8. History of allogenic organ transplant that requires use of immunosuppressives.
  9. Subject has active or uncontrolled infection including known HIV infection or known chronic hepatitis B or C.
  10. Any condition that, in the investigator's opinion, would interfere with evaluation of study treatment or interpretation of patient safety or study results.
  11. Uncontrolled intercurrent illness including those that do not respond to active medical intervention.
  12. Any contraindication to the use of known history of hypersensitivity to any immune therapy's drugs.
  13. Subjects must not have received any live vaccine within 28 days prior to the first dose of study treatment.
  14. Active autoimmune disease that requires systemic therapy, in the Investigator's opinion, may increase the risk of study participation.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:非ランダム化
  • 介入モデル:順次割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Cohort A (1 x 10^9 viral particles per injection)

Recurrent or Metastatic Head and Neck Cancer not scheduled for tumor resection surgery, 4 doses VLPONC-01 administered IT once weekly, with an additional follow-up safety visit 30 and 90 days post the final injection.

Weekly IT injections of 1 x 10^9 viral particles of VLPONC-01

他の名前:
  • VLPONC-01
  • IL-12 saRNA
  • VRP-IL-12
実験的:Cohort C - Group 1 (1 x 10^9 viral particles per injection plus Pembrolizumab)

Head and Neck Squamous Cell Carcinoma Patients scheduled for tumor resection surgery, 4 doses VLPONC-01 administered IT once weekly and 2 doses of 200mg neoadjuvant Pembrolizumab IV 3 weeks apart prior to tumor resection surgery, follow-up safety visit 30 days post-surgery and 90 days post final treatment.

Weekly IT injections of 1 x 10^9 viral particles of VLPONC-01

他の名前:
  • VLPONC-01
  • IL-12 saRNA
  • VRP-IL-12

200mg twice 3 weeks apart IV

他の名前:
  • ペムブロリズマブ
実験的:Cohort C - Group 2 (3 x 10^8 viral particles per injection plus Pembrolizumab)

Head and Neck Squamous Cell Carcinoma Patients scheduled for tumor resection surgery, 4 doses VLPONC-01 administered IT once weekly and 2 doses of 200mg neoadjuvant Pembrolizumab IV 3 weeks apart prior to tumor resection surgery follow-up safety visit 30 days post-surgery and 90 days post final treatment.

200mg twice 3 weeks apart IV

他の名前:
  • ペムブロリズマブ

Weekly IT injections of 3 x 10^8 viral particles of VLPONC-01

他の名前:
  • VLPONC-01
  • IL-12 saRNA
  • VRP-IL-12
実験的:Cohort C - Pembrolizumab only

Head and Neck Squamous Cell Carcinoma Patients scheduled for tumor resection surgery, 2 doses of 200mg neoadjuvant Pembrolizumab IV 3 weeks apart prior to tumor resection surgery, follow-up safety visit 30 days post-surgery and 90 days post final treatment.

200mg twice 3 weeks apart IV

他の名前:
  • ペムブロリズマブ

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Safety and tolerability
時間枠:First injection to 90-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C)

To assess the safety and tolerability of VLPONC-01. Safety will be based on the occurrence of any grade 3 or higher drug-related adverse events from the VLPONC-01 injections for non-surgery patients and any grade 3 or higher drug-related adverse events that result in a delay to tumor resection surgery.

First injection to 90-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C)

二次結果の測定

結果測定
メジャーの説明
時間枠
Levels of circulating IL-12
時間枠:First injection to 30-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C)

To assess the circulating blood levels of IL-12 after VLPONC-01 treatment compared to baseline to determine the occurrence and safety profile of potential systemic inflammatory responses.

First injection to 30-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C)
VLPONC-01 levels in tumor tissue
時間枠:First injection to tumor resection surgery

To detect levels of VLPONC-01 RNA in surgically resected tissue.

First injection to tumor resection surgery
Radiological Tumor Response
時間枠:First injection to tumor resection surgery (up to 3 months)

To assess the primary tumor response by RECIST.

First injection to tumor resection surgery (up to 3 months)
Pathological Tumor Response
時間枠:First injection to tumor resection surgery (up to 3 months)

To assess the primary tumor response by pathological analysis.

First injection to tumor resection surgery (up to 3 months)

その他の成果指標

結果測定
メジャーの説明
時間枠
Circulating levels of cytokines, chemokines, and immune markers
時間枠:First injection to 30-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C) through 90-day follow-up visit.

To assess the circulating levels cytokines, chemokines, and immune markers using a proteomics assay.

First injection to 30-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C) through 90-day follow-up visit.
ICH Changes in Tumor microenvironment
時間枠:First injection to 30-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C) through 90-day follow-up visit.

To assess levels of CD8+ T-cells, macrophages, and other immune cell populations in surgically resected tissue compared to biopsy tissue using immunohistochemistry.

First injection to 30-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C) through 90-day follow-up visit.
Changes in ctDNA related to Neoadjuvant treatment
時間枠:First injection to 30-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C) through 90-day follow-up visit.

To assess changes in ctDNA MRD treatment-related molecular response (Cohort C).

First injection to 30-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C) through 90-day follow-up visit.
Changes in cellular populations
時間枠:First injection to 30-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C) through 90-day follow-up visit.

To assess the changes in cellular populations in circulating blood using flow cytometry.

First injection to 30-day follow-up visit post-final injection (Cohort A) or post-surgery (Cohort C) through 90-day follow-up visit.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Fred M Baik, MD、Stanford University

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年5月13日

一次修了 (推定)

2027年12月30日

研究の完了 (推定)

2027年12月30日

試験登録日

最初に提出

2024年12月11日

QC基準を満たした最初の提出物

2024年12月11日

最初の投稿 (実際)

2024年12月16日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月21日

QC基準を満たした最後の更新が送信されました

2026年9月15日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する